Miravant to Initiate Photrex Confirmatory Phase III Trial in Europe

Miravant Medical Technologies, a pharmaceutical development company specializing in PhotoPoint photodynamic therapy, plans to conduct a confirmatory Phase III clinical trial for Photrex (rostaporfin, formerly known as SnET2) at investigational sites in Central and Eastern Europe and the UK.

Miravant has selected Kendle, a leading international contract research organization with locations worldwide, to provide clinical development services for the Phase III trial. The randomized, placebo-controlled study, reviewed by the FDA under a special protocol assessment, will evaluate a range of patients with wet age-related macular degeneration, including both classic and occult lesions.